Study of Daptomycin Safety and Efficacy for Complicated Skin and Skin Structure Infections (cSSSI) and Bacteremia in Renal Impairment



Status:Terminated
Conditions:Renal Impairment / Chronic Kidney Disease, Skin and Soft Tissue Infections, Infectious Disease
Therapuetic Areas:Dermatology / Plastic Surgery, Immunology / Infectious Diseases, Nephrology / Urology
Healthy:No
Age Range:18 - Any
Updated:9/7/2018
Start Date:April 19, 2010
End Date:June 12, 2012

Use our guide to learn which trials are right for you!

A Prospective, Multicenter, Randomized, Evaluator-blinded, Comparator-controlled Study to Describe the Safety and Efficacy of Daptomycin for the Treatment of Complicated Skin and Skin Structure Infections (cSSSI) and Staphylococcus Aureus Bacteremia Among Subjects With Moderate or Severe Renal Impairment

This is a multicenter, randomized, evaluator-blinded, comparator-controlled study.
Participants were to be randomized (1:1) to daptomycin or comparator, stratified by degree of
renal impairment (creatinine clearance [CLcr] 30 - 50 milliliters per minute [mL/min]
[moderate impairment] and <30 mL/min [severe impairment]) and by type of infection
(bacteremia and complicated skin and skin structure infections [cSSSI]) to create 4 cohorts
defined as follows:

- Cohort 1: Bacteremia and CLcr <30 mL/min

- Cohort 2: Bacteremia and CLcr 30 - 50 mL/min

- Cohort 3: cSSSI and CLcr <30 mL/min

- Cohort 4: cSSSI and CLcr 30 - 50 mL/min

Participants will be treated and evaluated for safety and microbiological and clinical
efficacy in accordance with their type of infection and degree of renal impairment. Peak and
trough samples will be collected to assess exposure to daptomycin for participants on Day 1
and following the 5th dose.


Inclusion Criteria:

- Written informed consent

- Male or female ≥18 years of age

- Diagnosis of cSSSI or Staphylococcus aureus (S. aureus) bacteremia

- Renal impairment of CLcr of 30 - 50 mL/min or CLcr <30 mL/min per Cockcroft-Gault
equation using actual body weight

- Functioning hemodialysis access and on stable regimen for those receiving dialysis

- In appropriate health for the study with no acute or chronic illnesses that could
adversely impact safety or ability to complete the study

Specific inclusion criteria for cSSSI:

- Presence of a wound infection, major abscess, severe carbunculosis, infected ulcers,
dialysis access site infection, or other type of infection in presence of complicating
factor

- At least 3 of the following symptoms, signs, or laboratory values of a skin infection:
elevated temperature; elevated white blood cell (WBC) count; pain; tenderness;
swelling; erythema greater than 1 centimeter (cm) beyond wound edge; induration; pus
formation

- Evidence of a Gram-positive infecting pathogen as indicated by positive Gram stain or
culture obtained within 96 hours prior to study drug administration

- Infection of sufficient severity to require parenteral antimicrobial therapy

Specific inclusion criteria for S. aureus bacteremia:

• Documented S. aureus bacteremia defined as at least one positive blood culture for S.
aureus obtained within 96 hours prior to the first dose of study medication

Exclusion Criteria:

- Pregnant or lactating females, or unwilling to practice barrier methods of birth
control

- Received an investigational drug (including experimental biologic agents) within 30
days of study entry

- Unable to discontinue use of HMG-CoA reductase inhibitor therapy while on study

- Known allergy or intolerance to daptomycin, penicillin, or vancomycin

- Active intravenous (IV) drug abuse

- Confirmed or suspected osteomyelitis, septic arthritis, meningitis, epidural abscess,
intra-abdominal infection, pneumonia, or infective endocarditis

- Required use of non-study systemic antibacterial agent with activity against target
pathogen

- History of muscular disease

- Neurological disease except stroke >6 months prior to study entry

- Intramuscular injection within 7 days of study drug administration

- Moribund clinical condition (high likelihood of death during next 3 days)

- Shock or hypotension (supine systolic blood pressure <80 millimeters of mercury
[mmHg])

- Body mass index (BMI) <18 or >40 kilograms per meter squared (kg/m^2) [BMI = weight
(kg)/height (m^2)]

- Known human immunodeficiency virus (HIV) infection with CD4 count ≤200
cells/millimeter (mm)^3

- Neutropenic participants with an absolute neutrophil count ≤500 cells/mm^3

- Anticipated to develop neutropenia absolute neutrophil count ≤500 due to prior or
planned chemotherapy

- Alanine aminotransferase (ALT) value >3 × upper limit of normal (ULN)

- Aspartate aminotransferase (AST) value >3 × ULN

- Total bilirubin values ≥ 1.5 x ULN associated with ALT values >3 x ULN

- Creatine phosphokinase (CPK) value >2 × ULN

- Hemoglobin <8 grams per deciliter (gm/dL)

- Unlikely to comply with study procedures or to return for evaluations

- History of rhabdomyolysis

- Prior enrollment into this study

- Infections caused by Gram-positive pathogens known to be resistant to daptomycin or
selected comparator agent

Specific exclusion criteria for cSSSI:

- Minor or superficial skin infections as the primary site of infection

- Cellulitis or erysipelas not associated with complicating factor as primary site of
infection

- Perirectal abscess, hidradenitis suppurativa, concomitant gangrene, myositis, multiple
infected ulcers at distant sites, necrotizing fasciitis, or infected third-degree burn
wounds

- Infections requiring emergency surgery

- Infections suspected or documented to be due exclusively to gram-negative, anaerobic,
or fungal organism

- Confirmed or suspected disorder that could interfere with the evaluations (for
example, primary skin disorders)

- Use of a topical antibiotic at the site of the infection

- Use of systemic antibacterial therapy for the infection for >24 hours within 48 hours
prior to start of study drug unless (a) infecting Gram-positive pathogen resistant to
therapy or (b) therapy administered for 3 or more days with worsening or no
improvement

- Planned surgical treatment that is considered curative of the infection

Specific exclusion criteria for S. aureus bacteremia:

- Has intravascular foreign material at the time the positive blood culture was drawn
(for example., intracardiac pacemaker wires, percutaneous or implanted venous
catheters, vascular grafts) unless material removed within 4 days after first dose of
study medication or approval of medical monitor (exceptions: vascular stents in place
for >6 months, permanent pacemaker attached via epicardial leads, or any dialysis
access device unless this material is felt to be infected)

- Prosthetic heart valve

- Cardiac decompensation or valve damage or both with high likelihood of valve surgery
in the 3 days after randomization

- Polymicrobial blood infection
We found this trial at
10
sites
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
?
mi
from
Azusa, CA
Click here to add this to my saved trials
?
mi
from
Columbus, OH
Click here to add this to my saved trials
?
mi
from
Decatur, GA
Click here to add this to my saved trials
?
mi
from
Mission, TX
Click here to add this to my saved trials
?
mi
from
Somers Point, NJ
Click here to add this to my saved trials
?
mi
from
Torrance, CA
Click here to add this to my saved trials
?
mi
from
Washington,
Click here to add this to my saved trials
West Reading, Pennsylvania 19611
?
mi
from
West Reading, PA
Click here to add this to my saved trials
?
mi
from
Winston-Salem, NC
Click here to add this to my saved trials